( rformance. No forward-looking statement...)New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine,Health

rformance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

GARDASIL(R) is a registered trademark of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.

Prescribing information and patient product information for GARDASIL(R) is attached and is also available at www.gardasil.com. -0-

MERCK & CO., INC.

Whitehouse Station, NJ 08889, USA                              9682301

----------------------------------------------------------------------


GARDASIL(R)

(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant

Vaccine)


DESCRIPTION


    GARDASIL* is a non-infectious recombinant, quadrivalent vaccine

prepared from the highly purified virus-like particles (VLPs) of the

major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1

proteins are produced by separate fermentations in recombinant

Saccharomyces cerevisiae and self-assembled into VLPs. The

fermentation process involves growth of S. cerevisiae on

chemically-defined fermentation media which include vitamins, amino

acids, mineral salts, and carbohydrates. The VLPs are released from

the yeast cells by cell disruption and purified by a series of

chemical and physical methods. The purified VLPs are adsorbed on

preformed aluminum-containing adjuvant (amorphous aluminum

hydroxyphosphate sulfate). The quadrivalent HPV VLP vaccine is a

sterile liquid suspension that is prepared 
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The
New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine
Shows Important Benefits of Eprodisate (KIACTA) Treatment for
Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering
Committee and Professor of Diabetes Medicine at Newcastle
University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American
College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab)
May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug
Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in
Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and
Experimental Therapeutics